Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RAINBO TransPORTEC MMRd-GREEN durvalumab adjuvant trial
NL-OMON59341Phase 3Recruiting
- Sponsor
- Leiden University Medical Center
- Start
- Jun 2022
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised trial of durvalumab in endometrial cancer (EC), sponsored by Leiden University Medical Center. Primary endpoint: 3-year recurrence-free survival. Started Jun 2022; status: recruiting.
02
Drugs
durvalumab
03
Conditions
endometrial cancer (EC)
Beyond the preview
Go deeper on NL-OMON59341.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59341.